GlassScriptPhysician profile
Pradeep R Gujja
NPI 1649465600
$9,706.97
in general payments reported to CMS, 2019-2025
23 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $178 · 2021: $83.17 · 2022: $2,977 · 2023: $3,724 · 2024: $294 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,921 · Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,920.71 |
| Food and Beverage | $1,738.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,302.46 | 2023-2025 | Azure Xt Dr Mri Surescan, Affera Mapping System |
| Medical Device Business Services, INC. | $2,242.76 | 2022 | |
| Biosense Webster, INC. | $2,125.87 | 2019-2025 | Carto 3, Nuvision Ice Catheter, Octaray Mapping Catheter |
| Boston Scientific Corporation | $1,763.45 | 2019-2025 | Watchman Flx, Watchman Access System, Cds - Mct/Cem Monitoring |
| Janssen Pharmaceuticals, INC | $538.58 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $216.87 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $101.44 | 2019-2020 | |
| Livanova USA, INC. | $49.01 | 2022 | |
| Lundbeck LLC | $44.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $42.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.94 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.41 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $29.75 | 2020-2022 | |
| Kestra Medical Technology Services, INC. | $29.65 | 2025 | Assure Wcd |
| Amgen INC. | $27.28 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $26.93 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.06 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.94 | 2020 | |
| Getinge USA Sales, LLC | $18.00 | 2023 | Cardiohelp |
| Cardiovascular Systems INC. | $13.10 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.71 | 2019 | |
| Daiichi Sankyo INC. | $11.51 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Gujja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.